General practitioners and pharmaceutical sales representatives: Quality improvement research

Quality and Safety in Health Care

Volumn 16, Issue 4, 2007, Pages 266-270

  Spurling, Geoffrey ^a   Mansfield, Peter ^b  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; DICLOFENAC; ROFECOXIB; ROSIGLITAZONE; SERTRALINE;

ARTICLE; CONTROLLED STUDY; DRUG COST; DRUG MARKETING; GENERAL PRACTITIONER; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HUMAN; MEDICAL AUDIT; MEDICAL PRACTICE; MEDICAL RESEARCH; MEDICAL STAFF; PERSONNEL MANAGEMENT; PRESCRIPTION; QUALITATIVE ANALYSIS; TOTAL QUALITY MANAGEMENT;

AUSTRALIA; DRUG INDUSTRY; DRUG UTILIZATION REVIEW; FAMILY PRACTICE; HEALTH SERVICES RESEARCH; HUMANS; MARKETING; POLICY MAKING; PRACTICE MANAGEMENT, MEDICAL; TIME FACTORS; TOTAL QUALITY MANAGEMENT;

EID: 34547911077     PISSN: 14753898     EISSN: None     Source Type: Journal    
DOI: 10.1136/qshc.2006.020164     Document Type: Article

References (23)

1. Moynihan R. Who pays for the pizza? Redefining the relationships between doctors and drug companies. 1: entanglement, BMJ 2003;326:1189-92.
2. CAM Newsletter Australia. http://www.cam-group.com/www_assets/ pages/downloads/CAM_Australia_Newsletter_Sep05.pdf (accessed on 4 January 2006).
3. Australian Institute of Health and Welfare. Labour force-medical, http://www.aihw.gov.au/labourforce/medical.cfm#gps (accessed 7 June 2006).
4. Jones MI, Greenfield SM, Bradley CP. Prescribing new drugs: qualitative study of influences on consultants and general practitioners. BMJ 2001;323:378-81.
5. Lexchin J. What information do physicians receive from pharmaceutical representatives? Can Fam Physician 1997;43:941-5.
6. Roughead EE, Gilbert AL, Harvey KJ. Self-regulatory codes of conduct: are they effective in controlling pharmaceutical representatives' presentations to general medical practitioners? Int J Health Serv 1998;28:269-79.
7. Ziegler MG, Lew P, Singer BC. The accuracy of drug information from pharmaceutical sales representatives. JAMA 1995;273:1296-8.
8. Caamano F, Figueiras A, Gestal-Otero JJ. Influence of commercial information on prescription quantity in primary care. Eur J Public Health 2002;12:187-91.
9. Mizik N, Jacobson R. Are physicians "easy marks"? Quantifying the effects of detailing and sampling on new prescriptions. Manage Sci 2004;50:1704-15.
10. Herings D, Blondeel L, Habraken H. The effect of industry-independent drug information on the prescribing of benzodiazepines in general practice. Eur J Clin Pharmacol 1994;46:501-5.
11. Muijrers PE, Grol RP, Sijbrandij J, et al. Pharmaceutical care and its relationship to prescribing behaviour of general practitioners. Pharm World Sci 2006;28:302-8.
12. Norris P, Herxheimer A, Lexchin J, et al. Drug promotion: what we know, what we have yet to learn. Geneva: World Health Organization, 2005, http://www.who.int/medicines/areas/rational_use/drugPromodhai.pdf (accessed 24 April 2005).
13. Caudill TS, Johnson MS, Rich EC, et al. Physicians, pharmaceutical sales representatives, and the cost of prescribing. Arch Fam Med 1996;5:201-6.
14. Walkins C, Harvey I, Carthy P, et al. Attitudes and behaviour of general practitioners and meir prescribing costs: a national cross sectional survey. Qual Saf Health Care 2003;12:29-34.
15. Thomson AN, Craig BJ, Barham PM. Attitudes of general practitioners in New Zealand to pharmaceutical representatives. Br J Gen Pract 1994;44:220-3.
16. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000;283:373-80.
17. Chew LD, O'Young TS, Hazlet TK, et al. A physician survey of the effect of drug sample availability on physicians' behaviour. J Gen Intern Med 2000;15:478-83.
18. Wolf BL. Drug samples: benefit or bait? JAMA 1998;279:1698-9.
19. Finch J. Interprofessional education and teamworking: a view from the education providers. BMJ 2000;321:1138-40.
20. Stevenson K, Baker R, Farooqi A, et al. Features of primary health care teams associated with successful quality improvement of diabetes care: a qualitative study. Fam Pract 2001;18:21-6.
21. Brody H. The company we keep: why physicians should refuse to see pharmaceutical representatives. Ann Fam Med 2005;3:82-5.
22. Mansfield PR, Lexchin J, Wen LS, et al. Educating health professionals about drug and device promotion: advocates' recommendations. PLoS Med 2006;3:e451.
23. Bischoff MB. Successful pharmaceutical selling: frank advice from the front lines. New York: McGraw Hill, 1997.